New synthetic corticosteroids inhibit Epstein–Barr virus release

[1]  F. Cadegiani.  Repurposing existing drugs for COVID-19: an endocrinology perspective , 2020, BMC Endocrine Disorders.

[2]  P. Vidalain,et al.  Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening: efficacy of decitabine and valganciclovir alone or in combination. , 2020, Antiviral research.

[3]  M. Barbaccia,et al.  Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2 , 2020, Biochemical Pharmacology.

[4]  F. Cadegiani,et al.  Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS) , 2020, Medical Hypotheses.

[5]  Mathias Uhlen,et al.  Current Status of COVID-19 Therapies and Drug Repositioning Applications , 2020, iScience.

[6]  C. Szabó,et al.  Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease , 2020, Critical Care.

[7]  I. Zavarzin,et al.  Novel steroidal 1,3,4-thiadiazines: Synthesis and biological evaluation in androgen receptor-positive prostate cancer 22Rv1 cells. , 2019, Bioorganic chemistry.

[8]  P. Farrell.  Epstein-Barr Virus and Cancer. , 2019, Annual review of pathology.

[9]  P. Vidalain,et al.  Screening and evaluation of antiviral compounds against Equid alpha-herpesviruses using an impedance-based cellular assay. , 2019, Virology.

[10]  L. Young,et al.  Epstein–Barr virus: more than 50 years old and still providing surprises , 2016, Nature Reviews Cancer.

[11]  S. Swaminathan,et al.  Spironolactone blocks Epstein–Barr virus production by inhibiting EBV SM protein function , 2016, Proceedings of the National Academy of Sciences.